Cigna Corporation

NYSE:CI

Medical - Healthcare Plans

Healthcare
$285.37 -1.56%

-$4.44 today

Market cap
$75.20B
Beta
0.30
P/E (TTM)
11.7
EPS (TTM)
$23.95
Dividend yield
2.19%
52W Low $239.51High $338.89

Volume 2.49M

Average 1.61M

CI Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Cigna CorporationNYSE: CI

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development remains negative

Q3 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How CI compares with its peers on the latest reported figures

  • CI's LTM Sep 2026 research & development of $0 is the highest of the 9 companies compared; the peer median is $0.
  • Research & development amounts to 0.0% of revenue for CI, versus a peer median of 0.0%.
CI Competitors Peer median
Research & Development for CI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CICigna CorporationLTM Sep 2026$0 ——0.0%
UNHUnitedHealth Group IncorporatedLTM Sep 2026$0 ——0.0%
CVSCVS Health CorporationLTM Jun 2026$0 ——0.0%
ELVElevance Health Inc.LTM Sep 2026$0 ——0.0%
HUMHumana Inc.LTM Sep 2026$0 ——0.0%
CNCCentene CorporationLTM Jun 2026$0 ——0.0%
MOHMolina Healthcare, Inc.LTM Sep 2026$0 ——0.0%
OSCROscar Health, Inc.LTM Jun 2026$0 ——0.0%
ALHCAlignment Healthcare, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding CI) $0——0.0%

Competitors are the stored peer set for CI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue174.07B180.52B195.27B247.12B274.95B
Cost of Revenue151.12B157.02B170.09B221.16B248.97B
Gross Profit22.95B23.5B25.18B25.96B25.99B
Gross Margin13.2%13.0%12.9%10.5%9.5%
Research & Development00000
Selling, General & Admin12.79B13.05B14.32B14.57B14B
Operating Expenses15.01B15.05B16.64B16.55B16.86B
Depreciation & Amortization2.92B2.94B3.04B2.78B2.78B
EBITDA11.09B11.52B12.07B12.47B11.75B
EBITDA Margin6.4%6.4%6.2%5.0%4.3%
Operating Income7.94B8.45B8.54B9.42B9.13B
Operating Margin4.6%4.7%4.4%3.8%3.3%
Interest Income00000
Interest Expense1.21B1.23B1.45B1.44B1.38B
Other Income / Expenses(1.15B)(53M)(3.02B)(4.15B)(1.54B)
Income Before Tax6.79B8.4B5.51B5.27B7.59B
Pre-Tax Margin3.9%4.7%2.8%2.1%2.8%
Income Tax Expense1.37B1.62B141M1.49B1.35B
Net Income5.37B6.7B5.16B3.43B5.96B
Net Margin3.1%3.7%2.6%1.4%2.2%
EPS (Basic)15.8921.6617.5712.2522.30
EPS (Diluted)15.7521.4117.3912.1222.17
Weighted Avg Shares337.96M313.07M296.88M280.29M265.95M
Weighted Avg Shares (Diluted)340.97M313.07M296.88M283.22M265.95M

Cigna Corporation

NYSE:CI

Intrinsic Alpha fair value

Locked

Current Price

$285.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.